Navigation Links
Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
Date:3/13/2008

nd any other factors referenced in our annual information form and other filings with the applicable Canadian securities regulatory authorities or the SEC. Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

(TM)HemoStream is a trademark of Rex Medical, LP used under license by Angiotech.

CONTACT: Angiotech Contact: Deirdre Neary, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... January 14, 2014 Kerr Corporation, a leading ... and additional how-to information about dual arch impressions on its ... Dual Arch Impressions,” the blog entry serves up a list ... houses a step-by-step demonstration by Dr. David Little as he ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... (NYSE Amex: CXM ) today announced plans to ... and Drug Administration (FDA) seeking marketing clearance of its ... is an advanced wound care management medical device, which ... by physicians in patients with topical wounds, which include ...
... study from Thomson Reuters released today shows explosive growth in ... rest of the world. , At this pace, China ... The study, Global Research Report: China , informs policymakers ... current place in world science. The study is part of ...
... 1 Pharmasset, Inc. (Nasdaq: VRUS ) today announced ... Association for the Study of Liver Diseases (AASLD) on Monday, ... management will review Pharmasset,s progress on the programs that are ... simultaneous webcast of this event via the internet, log on ...
Cached Biology Technology:Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4China's Research Output More Than Doubled Since 2004, Thomson Reuters Study Reveals 2Pharmasset to Webcast an Investor Event from the AASLD Meeting 2Pharmasset to Webcast an Investor Event from the AASLD Meeting 3Pharmasset to Webcast an Investor Event from the AASLD Meeting 4
(Date:4/24/2014)... play a crucial role in the global-scale cycling ... atmosphere. Now scientists at Scripps Institution of Oceanography ... forward in understanding the microscopic underpinnings of these ... make new cells, a substantial portion of that ... a buffet of edible molecules collectively called "dissolved ...
(Date:4/24/2014)... WEST LAFAYETTE, Ind. - Purdue and West Virginia University ... the golden eagle, providing a bird,s-eye view of eagle ... , Their study calls into question long-held assumptions ... not be as sensitive to ultraviolet light as previously ... have a sharper sense of smell than researchers realized. ...
(Date:4/24/2014)... a commercially important sugar used as a sweetener, ... for synthesizing riboflavin and several antiviral drugs. Genetic ... the bacteria,s ability to produce D-ribose is a ... of this valuable chemical, as described in an ... journal from Mary Ann Liebert, Inc., publishers. The ...
Breaking Biology News(10 mins):Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 2Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 3Genome yields insights into golden eagle vision, smell 2
... program that trains emergency medical service technicians (EMS) to read ... and expedite treatment for the severe heart condition known as ... attack, has excellent results and should become the standard of ... of the Canadian Journal of Cardiology . ...
... cells organized in thousands of small divots. Hit these cells ... candidate for a cancer drug. But a review published this ... argues that these 2D models in fact offer very ... and may often give researchers misleading results. "Up ...
... scientific research has deep roots in the history of ... off spectacularly from launch pads across the disciplines of ... and a sea change in a scientific culture now ... science, crowd-sourced science, DIY research, volunteer monitoring, community participatory ...
Cached Biology News:ECGs administered by paramedics can speed treatment for severe heart attacks 2ECGs administered by paramedics can speed treatment for severe heart attacks 33-D tumor models improve drug discovery success rate 23-D tumor models improve drug discovery success rate 3Inaugural cross-disciplinary Public Participation in Scientific Research conference 2